Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2008

01-08-2008 | Original Paper

Expression and Prognostic Roles of Eag1 in Resected Esophageal Squamous Cell Carcinomas

Authors: Xiang-Wu Ding, Xiang-Gui Wang, He-Sheng Luo, Shi-Yun Tan, Shan Gao, Bing Luo, Hua Jiang

Published in: Digestive Diseases and Sciences | Issue 8/2008

Login to get access

Abstract

Expression of Eag1 was detected in resected esophageal squamous cell carcinomas tissues and matched tissues by immunohistochemistry and RT-PCR. Positive expression of Eag1 protein was 75% (51/68), and mRNA was 73% (8/11) in primary cancer tissues. Eag1 protein positively stained in all 10 metastatic lymph nodes. Eag1 protein and mRNA were negatively expressed in all non-cancerous matched tissues. Eag1 protein was associated with depth of penetration (P = 0.023), but not associated with other clinicopathological factors. Eag1 protein positive group had a significantly shorter survival time than the negative group (P = 0.005). Survival rates at each time-point for the positive group were lower than that for the negative group (P = 0.006), and Eag1 was identified as an independent prognostic factor of long-term survival (P = 0.016). In conclusion, Eag1 was aberrantly expressed in ESCC and correlated with poor prognosis after surgery.
Literature
1.
Liu JF, Wang QZ, Hou J (2004) Surgical treatment for cancer of the oesophagus, gastric cardia in Hebei. China Br J Surg 91:90–98CrossRef
2.
Latour I, Louw DF, Beedle AM, Hamid J, Sutherland GR, Zamponi GW (2004) Expression of T-type calcium channel splice variants in human glioma. Glia 48:112–119PubMedCrossRef
3.
Wang XT, Nagaba Y, Cross HS, Wrba F, Zhang L, Guggino SE (2000) The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am J Pathol 157:1549–1562PubMed
4.
Kim CJ, Cho YG, Jeong SW, Kim YS, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY, Park WS (2004) Altered expression of KCNK9 in colorectal cancers. APMIS 112:588–594PubMedCrossRef
5.
Bustin SA, Li SR, Dorudi S (2001) Expression of the Ca2+-activated chloride channel genes CLCA1 and CLCA2 is downregulated in human colorectal cancer. DNA Cell Biol 20:331–333PubMedCrossRef
6.
Abdel-Ghany M, Cheng HC, Elble RC, Lin H, DiBiasio J, Pauli BU (2003) The interacting binding domains of the beta(4) integrin and calcium-activated chloride channels (CLCAs) in metastasis. J Biol Chem 278:49406–49416PubMedCrossRef
7.
Bennet ES, Smith BA, Harper JM (2004) Voltage-gated NaC channels confer invasive properties on human prostate cancer cells. Pflugers Arch 447:908–914CrossRef
8.
Schonherr R (2005) Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol 205:175–184
9.
10.
Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stuhmer W (2005) Role of voltage-gated potassium channels in cancer. J Membr Biol 205:115–124PubMedCrossRef
11.
Wang Z (2004) Roles of KC channels in regulating tumor cell proliferation and apoptosis. Pflugers Arch 448:274–286PubMedCrossRef
12.
Patel AJ, Lazdunski M (2004) The 2P-domain KC channels: role in apoptosis and tumorigenesis. Pflugers Arch 448:261–273PubMedCrossRef
13.
14.
Camacho J, Sanchez A, Stuhmer W, Pardo LA (2000) Cytoskeletal interactions determine the electrophysiological properties of human EAG potassium channels. Pflugers Arch 441:167–174PubMedCrossRef
15.
Pardo LA, Brüggemann A, Camacho J, Stühmer W (1998) Cell cycle-related changes in the conducting properties of r-eag K+ channels. J Cell Biol 143:767–775PubMedCrossRef
16.
Brüggemann A, Stühmer W, Pardo LA (1997) Mitosis-promoting factor-mediated suppression of a cloned delayed rectifier potassium channel expressed in Xenopus oocytes. Proc Natl Acad Sci USA 94:537–542PubMedCrossRef
17.
Occhiodoro T, Bernheim L, Liu JH, Bijlenga P, Sinnreich M, Bader CR, Fischer-Lougheed J (1998) Cloning of a human ether-a-go-go potassium channel expressed in myoblasts at the onset of fusion. FEBS Lett 434:177–182PubMedCrossRef
18.
Meyer R, Schonherr R, Gavrilova-Ruch O, Wohlrab W, Heinemann SH (1999) Identification of ether à go-go and calcium-activated potassium channels in human melanoma cells. J Membr Biol 171:107–115PubMedCrossRef
19.
Meyer R, Heinemann SH (1998) Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol 508:49–56PubMedCrossRef
20.
Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, Prevarskaya N (2001) Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether. a-gogo K+ channel. Recept Channels 7:345–356PubMed
21.
Farias LM, Ocana DB, Diaz L, Larrea F, Avila-Chavez E, Cadena A, Hinojosa LM, Lara G, Villanueva LA, Vargas C, Hernandez-Gallegos E, Camacho-Arroyo I, Duenas-Gonzalez A, Perez-Cardenas E, Pardo LA, Morales A, Taja-Chayeb L, Escamilla J, Sanchez-Pena C, Camacho J (2004) Ether à go-go potassium channels as human cervical cancer markers. Cancer Res 64:6996–7001PubMedCrossRef
22.
Patt S, Preussat K, Beetz C, Kraft R, Schrey M, Kalff R, Schonherr K, Heinemann SH (2004) Expression of ether à go-go potassium channels in human gliomas. Neurosci Lett 368:249–253PubMedCrossRef
23.
Mello de Queiroz F, Suarez-Kurtz G, Stuhmer W, Pardo LA (2006) Ether à go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 5:42CrossRef
24.
Ding XW, Yan JJ, An P, Lü P, Luo HS (2007) Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines. World J Gastroenterol 13:1257–1261PubMed
25.
Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knotgen H, Sanchez A, Rubio ME, Martin S, Schliephacke T, Jenke M, Radzun HJ, Stuhmer W, Pardo LA (2006) Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 5:41PubMedCrossRef
26.
Pardo LA, del Camino D, Sanchez A, Alves F, Bruggemann A, Beckh S, Stuhmer W (1999) Oncogenic potential of EAG K(+) channels. EMBO J 18:5540–5547PubMedCrossRef
27.
Mega S, Miyamoto M, Ebihara Y, Takahashi R, Hase R, Li L, Shichinohe T, Kawarada Y, Uehara H, Kaneko H, Hashimoto H, Murakami Y, Itoh T, Morikawa T, Kondo S (2005) Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. Dis Esophagus 18:109–113PubMedCrossRef
28.
Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A, Verde PE, Eisenberger CF, Peiper M, Rehders A, Esch JS, Knoefel WT, Hosch SB (2006) Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 6:165PubMedCrossRef
29.
Xue LY, Ren LQ, Luo W, Guan XJ, Zou SM, Zheng S, Bi R, Xie YQ, He ZG, Lu N (2007) Expression of Fas, Fas ligand, Fas-associated death domain protein, caspase 8 and mutant P53 protein in esophageal squamous cell carcinoma. Zhonghua Yi Xue Za Zhi 87:150–154PubMed
30.
Uehara H, Miyamoto M, Kato K, Cho Y, Kurokawa T, Murakami S, Fukunaga A, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Shichinohe T, Kawarada Y, Itoh T, Okushiba S, Kondo S, Katoh H (2005) Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma. J Surg Oncol 92:109–115PubMedCrossRef
31.
Wada S, Noguchi T, Takeno S, Kawahara K (2006) PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma. Ann Surg Oncol 13:961–966PubMedCrossRef
32.
Ishiyama A, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A (2006) PTCH gene expression as a potential marker for esophageal squamous cell carcinoma. Anticancer Res 26:195–198PubMed
33.
Takashima N, Ishiguro H, Kuwabara Y, Kimura M, Haruki N, Ando T, Kurehara H, Sugito N, Mori R, Fujii Y (2006) Expression and prognostic roles of PABPC1 in esophageal cancer: correlation with tumor progression and postoperative survival. Oncol Rep 15:667–671PubMed
34.
Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, Mandruzzato S, Del Bianco P, Ruol A, Zaninotto G, Zanovello P (2006) Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 119:1717–1722PubMedCrossRef
Metadata
Title
Expression and Prognostic Roles of Eag1 in Resected Esophageal Squamous Cell Carcinomas
Authors
Xiang-Wu Ding
Xiang-Gui Wang
He-Sheng Luo
Shi-Yun Tan
Shan Gao
Bing Luo
Hua Jiang
Publication date
01-08-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0116-7

Other articles of this Issue 8/2008

Digestive Diseases and Sciences 8/2008 Go to the issue

Original Paper

Gastrointestinal Manifestations of Henoch-Schonlein Purpura

Original Paper

Helicobacter pylori Stool Antigen (HpSA) Tests in Children Before and After Eradication Therapy: Comparison of Rapid Immunochromatographic Assay and HpSA ELISA

Original Paper

Dietary Lipids Alter the Effect of Steroids on the Transport of Fructose Following Intestinal Resection in Rats

Original Paper

Acid-suppression Therapy Offers Varied Laryngopharyngeal and Esophageal Symptom Relief in Laryngopharyngeal Reflux Patients

Original Paper

Protective Effects of Diets Supplemented with Omega-3 Polyunsaturated Fatty Acids and Calcium Against Colorectal Tumor Formation

Original Paper

RETRACTED ARTICLE: Gastric Changes Following Colchicine Therapy in Patients with FMF
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits